Sutro Biopharma, Inc. (STRO) is a Healthcare stock trading at $20.96 (as of 2026-08-21), with a market capitalization of $347.32M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Sutro Biopharma develops protein therapeutics for cancer and autoimmune disorders, using its integrated cell-free protein synthesis and site-specific conjugation platform (XpressCF+), and it makes money through its operating business, which was reported as 0.0B revenue in the latest quarter.
As a clinical-stage biotech, profitability depends on advancing its pipeline, since current reported revenue is essentially zero and the latest quarter shows a sharply negative operating margin.
| Revenue | $0.0B |
Business quality (Solid): Clarity is high on business model and pipeline stage, but the financial snapshot shows negligible reported revenue, so near term economics depend heavily on future clinical and commercialization progress.
| Price | $20.96 |
| Market Cap | $347.32M |
| Price / Sales | 7.15 |
| Revenue (TTM) | $102.48M |
| Net Margin | -186.5% |
| Revenue Growth (YoY) | 65.2% |
| EPS Growth (YoY) | 659.8% |
| Altman Z-Score | -9.09 (distress) |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Top Institutional Holder | BVF INC/IL ($31.18M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Jane Chung |
| Employees | 269 |
| Country | US |
| IPO Date | 2018-09-27 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.